Skip to main content


Moberg Pharma’s share is listed on the main list at NASDAQ OMX Stockholm. Moberg Pharma’s goal is to create value and provide attractive shareholder returns through the successful commercialization of its pipeline assets.

In 2019, the focus is on advancing the company's phase 3 development programs and to continue commercialization preparations to maximize value and create future growth.


Aktiekurs 17 Jun 2013 14:30
33.90 kr
1.19 %

Latest report

2020-08-11 Interim report April – June 2020


Next calendar event: 2020-11-10 Interim report for July 2019 - September 2020

Contact Investor

Anna Ljung, CEO
Tel. +46 (0)8 522 307 01

Peter Wolpert, Executive Chairman and Founder
Tel: +46 (0)8 522 307 08



Get our latest press releases and reports